Transferrin Receptor-Targeted Lipid Nanoparticles for Delivery of an Antisense Oligodeoxyribonucleotide against Bcl-2-Reference-Cited by-同舟云学术

Transferrin Receptor-Targeted Lipid Nanoparticles for Delivery of an Antisense Oligodeoxyribonucleotide against Bcl-2

Published:2008-12-15 Issue:1 Volume:6 Page:221-230
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Yang Xiaojuan¹,Koh Chee Guan¹,Liu Shujun¹,Pan Xiaogang¹,Santhanam Ramasamy¹,Yu Bo¹,Peng Yong¹,Pang Jiuxia¹,Golan Sharon¹,Talmon Yeshayahu¹,Jin Yan¹,Muthusamy Natarajan¹,Byrd John C.¹,Chan Kenneth K.¹,Lee L. James¹,Marcucci Guido¹,Lee Robert J.¹

Affiliation:

1. Division of Pharmaceutics, College of Pharmacy, NSF Nanoscale Science and Engineering Center (NSEC) for Affordable Nanoengineering of Polymeric Biomedical Devices (CANPBD), Department of Chemical and Biomolecular Engineering, NCI Comprehensive Cancer Center (CCC), Department of Molecular and Cellular Biochemistry, and Division of Hematology and Oncology, The Ohio State University, Columbus, Ohio 43210, and Department of Chemical Engineering, Technion - Israel Institute of Technology, Haifa 32000, Israel

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/mp800149s

Reference31 articles.

1. Progress in Antisense Technology

2. A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of nanomedicines for the treatment of Alzheimer’s disease: Raison d’être, strategies, challenges and regulatory aspects;Ageing Research Reviews;2024-07

2. Tailoring lipid nanoparticles for T-cell targeting in allergic asthma: Insights into efficacy and specificity;European Journal of Pharmaceutics and Biopharmaceutics;2024-05

3. Transferrin receptor in primary and metastatic breast cancer: Evaluation of expression and experimental modulation to improve molecular targeting;PLOS ONE;2023-12-20

4. RNAi therapies: Expanding applications for extrahepatic diseases and overcoming delivery challenges;Advanced Drug Delivery Reviews;2023-10

5. Inhibitory effect of obatoclax mesylate-Loaded nanoparticles on lung cancer through Bcl-2 pathway;Materials Express;2023-02-01